Sutro Biopharma Net Income Over Time
| STRO Stock | USD 14.88 0.73 4.68% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value—what Sutro Biopharma's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTV | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (71.8 M) | (58.4 M) | (27.7 M) | (58.5 M) | (52.6 M) | (55.3 M) |
| DTIL | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (21.1 M) | (46 M) | (92.9 M) | (109 M) | (30.6 M) | (111.6 M) | (61.3 M) | 7.2 M | 6.5 M | 6.8 M |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| MGX | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (43.6 M) | (68.3 M) | (78.1 M) | (78.1 M) | (70.3 M) | (73.8 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sutro Biopharma financial statement analysis. It represents the amount of money remaining after all of Sutro Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Sutro Biopharma | STRO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 111 Oyster Point |
| Exchange | NASDAQ Exchange |
USD 14.88
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Sutro Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.